|
|
|
|
|
|
|
12.11.26 - 22:03
|
Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Progress (Business Wire)
|
|
|
FDA alignment establishes path to complete the pivotal Phase 2 trial of RP-A501 in Danon disease; dosing completion expected by mid-2027
October Danon disease investor webinar highlighted updated longer-term RP-A501 Phase 1 findings and encouraging initial safety observations in the first three patients treated under the modified Pivotal Phase 2 protocol
Dosing initiated in the Phase 1 trial of RP-A701 for BAG3-associated dilated cardiomyopathy
KRESLADI™ achieved commercial readiness on October 1, 2026; Qualified Treatment Centers activated and ready to begin commercial patient onboarding
Cash, cash equivalents and investments of approximately $279.4 million as of September 30, 2026, including the initial $35 million Hercules draw, are expected to fund planned operations into Q3 2028. Additional borrowings could extend runway into 2029, subject to borrowing conditions, draw timing and amounts, and operating expenditures.CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a full...
|
|
|
|
|
|
|
|
|
|
|
06.10.26 - 22:15
|
Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital (Business Wire)
|
|
|
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced that it has entered into a credit facility agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $150 million. The facility strengthens Rocket's financial position and provides access to additional capital to support execution of its pivotal Phase 2 study of RP-A501 for Danon disease and continued advancement of its broader cardiovascular pipeline.
“Building on the sale of our priority review voucher, this financing diversifies our sources of capital and strengthens our ability to execute and deliver on our cardiovascular strategy,” said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals. “The staged structure provides flexibility to align additional funding with progress across our programs. We remain focused ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
